Figure 9. High GPRC5A is associated with poor survival and chemotherapy resistance in HGSC patients.

• A
  Flow diagram of patients for the HGSC TMA.
• B
  Representative immunostainings for GPRC5A scoring in HGSC primary and metastatic tumors. For maximum intensity scores, an optical 4‐point scale (0: negative, 1: mild, 2: moderate, and 3: high) was used. For survival analyses, a 2‐point scale (low: scores 0–2 and high: score 3) was used. Scale bars: 200 μm.
• C, D
  Kaplan–Meier survival curves illustrate the overall (OS) and progression‐free (PFS) survival of patients with high or low GPRC5A. In primary tumors, mean OS for GPRC5A^high was 39 months vs. 56 months for GPRC5A^low (C). In patients with metastatic tumors, mean OS for GPRC5A^high was 37 months vs. 60 months for GPRC5A^low. Mean PFS in metastatic tumors was 20 months for GPRC5A^high vs. 35 months for GPRC5A^low (D). No significant difference in mean PFS in primary tumors.
• E
  Correlation of maximum GPRC5A intensity with objective response rate (ORR) and treatment sensitivity (platinum alone or in combination with taxane).
• F–I
  Kaplan–Meier survival estimates for the PFS of patients with high or low (top 25% vs. bottom 25%) GPRC5A (F), EPHA2 (G), GPRC5A + EPHA2 (H), and GPRC5A + EPHA2 + RSK1(RPS6KA1) + RSK2(RPS6KA3)‐combined (I) mRNA expression. Mean PFS for GPRC5A + EPHA2^high was 15 months vs. 26 months for GPRC5A + EPHA2^low (H). Mean PFS for GPRC5A + EPHA2 + RPS6KA1/3^high was 14 months vs. 31 months for GPRC5A + EPHA2 + RPS6KA1/3^low (I).

Data information: In (C, D and F–I), logrank test was used. In (E), Pearson chi‐square test was used.